Dutch Decision Invalidates Truvada SPC
Basic Patent Did Not Identify Emtricitabine
Executive Summary
Gilead’s Truvada is not entitled to an SPC in the Netherlands because the patent on which the SPC application referred mentions only one of the two active ingredients in the combination antiretroviral.